Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa

Abstract

AbstractBackgroundFoslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.ObjectivesAssess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).MethodsPearson correlations between sleep (Parkinson's Disease Sleep Scale‐2 [PDSS‐2]) and quality of life (QoL; Parkinson's Disease Questionnaire‐39), motor experiences of daily living (m‐EDL; Movement Disorder Society‐Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS‐2 score.ResultsBaseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m‐EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m‐EDL.ConclusionsImproved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.